Latest Announcements

Granules India Ltd reported Q2 and H1 FY27 earnings, with revenue growing 20% YoY to INR15,600 million, and EBITDA and PAT increasing 21% and 39% respectively. The company's growth strategy has multiple pillars, including controlled substances, complex generics, geographical expansion, and peptide CDMO.

Indian Hume Pipe Company Ltd published its unaudited financial results for the 2nd quarter and 1st half year ended September 30, 2026. The company reported a net profit of INR 2274.88 lakhs and an earnings per share of INR 4.32 for the quarter, and INR 4631.83 lakhs and INR 8.79 for the half year.

Granules India Limited has informed the Exchange about the Transcript of the Earnings Conference call for Q2 and the half-year of FY27. The company's revenue grew 20% year-on-year to INR15,600 million, crossing INR15,000 million in quarterly revenue for the first time in its history. EBITDA grew 21%, while PAT increased 39% to INR1,818 million. The company has also uploaded its detailed quarterly presentation and will submit a comprehensive response within 15 business days detailing its corrective and preventive actions following a cGMP inspection by the U.S. FDA.

KPI Green Energy Limited has informed the Exchange regarding the energization of further capacity under its 250 MW / 350 MWp Solar Power Project and the 370 MW / 677 MWp Hybrid Power Project. The company has cumulatively energized 300.8 MWp out of 350 MWp capacity under the said Solar IPP Project and 510.7 MWp out of 677 MWp capacity under the said Hybrid IPP Project, comprising 449.2 MWp of solar and 61.5 MW of wind capacity.

KPI Green Energy Ltd has informed the exchange regarding the energization of further capacity under its 250 MW / 350 MWp Solar Power Project and 370 MW / 677 MWp Hybrid Power Project at Bharuch, Gujarat. The company has cumulatively energized 300.8 MWp out of 350 MWp capacity under the said Solar IPP Project and 510.7 MWp out of 677 MWp capacity under the said Hybrid IPP Project.

Symbiotec Pharmalab Limited has signed a 10-year, take-or-pay contract development and manufacturing agreement with a European alternative protein innovator to manufacture fermentation-based alternative protein. The agreement reserves dedicated capacity for the partner at Symbiotec's Ujjain campus for the full term.

Fujiyama Power Systems Limited has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with revenue from operations at Rs. 13,068 Mn, up 130.1% YoY, and EBITDA at Rs. 2,229 Mn, up 116.4% YoY.

Arvind SmartSpaces Ltd announces record Q2 performance with 110% surge in bookings, driven by successful launches and strong sustenance sales. The company revises its FY27 bookings growth guidance upwards, expecting 70 to 75% year-on-year growth.

Patanjali Foods Limited has submitted a disclosure under regulation 30 of SEBI LODR, announcing its expansion into emerging consumption channels, including e-commerce, and strengthening its institutional business, with a 50% y-o-y growth.

Arvind SmartSpaces Limited has announced its revised press release for unaudited financial results for Q2 & H1 FY27, with a 110% surge in bookings and 77% increase in collections.

Patanjali Foods Ltd disclosed under Regulation 30 of SEBI LODR, informing about its press release on accelerating diversification, strengthening digital and institutional presence, and growing e-commerce and institutional business.

Coffee Day Enterprises Ltd received a favorable order from the Securities Appellate Tribunal (SAT) on November 5, 2026, setting aside a penalty of Rs. 26 Crores imposed by SEBI in January 2023. The company is evaluating its next course of action.

Fredun Pharmaceuticals Ltd reported a 94% YoY growth in net profit, 92% YoY growth in EBITDA, and 87% YoY growth in revenue for H1 FY27. The company's diversified portfolio spans generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key business highlights include the acquisition of Furlicks, a 26% stake in Goodman Vetcare, and the launch of PAWTALKS as a pet healthcare knowledge platform.

DLF Ltd has announced a proposed joint venture with Everstone Group to invest in IREO group, with DLF intending to invest approximately Rs 3,750 crore for a majority stake. The joint venture aims to deliver high-quality developments across Delhi, Gurugram, and other regions.

Britannia Industries Ltd has announced its Q2 FY26-27 results, with revenue from operations at Rs 5,542 crores, a 16.6% increase from the previous quarter, and profit after tax at 13.0% of revenue, a 10.2% increase from the previous quarter. The company has also reported a 12-month growth of 13.1% in revenue from operations and a 12.5% increase in profit after tax.

Manaksia Coated Metals & Industries Ltd successfully raises ₹150 crore through QIP, issue fully subscribed, with the capital raise strengthening its balance sheet and enhancing financial flexibility to support its upcoming strategic projects.

Manaksia Coated Metals & Industries Limited has successfully raised ₹150 crore through a Qualified Institutional Placement (QIP), with the issue fully subscribed. The capital raise strengthens the company's balance sheet and enhances financial flexibility to support its upcoming strategic projects.

Sai Life Sciences Ltd has released its Q2 FY 2026-27 financial results, showing a 23% year-on-year growth in revenue and a 28% EBITDA margin. The company has also reported a strong business momentum and progress across its key strategic priorities.

Sai Life Sciences Limited has informed the Exchange about Investor Presentation, detailing its Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026. The company reports a healthy performance, with revenue growing by 23% year-on-year, and EBITDA margins standing at 28%. The presentation highlights the company's growing traction with global pharmaceutical companies, increasing adoption of its integrated outsourcing model, and continued progress in building capacity and capabilities.

Sai Life Sciences Ltd reported strong Q2 FY27 revenue growth of 23% YoY, sustaining EBITDA margin. Revenue from Operations was ₹1,213 Cr for H1FY27 compared to ₹1,034 Cr in H1FY26, an increase of 17%. EBITDA stood at ₹335 Cr for H1FY27 compared to ₹281 Cr in H1FY26, an increase of 19%. PAT stood at ₹172 Cr for H1FY27 compared to ₹144 Cr in H1FY26, an increase of 19%. Incurred Capex of ₹621 Cr in H1FY27.